Robert Darwin

Recent examples of Robert’s work includes acting for:

Private Equity/M&A

• Sylvan Group on its US$600 million investment into Juniper Biologics.
• Merck KGaA on strategic M&A, including its up to €1 billion immuno-oncology collaboration with F-Star and licensing and collaboration arrangements, followed by the subsequent restructure of those arrangements.
• Savillex Corporation, a portfolio company of private equity fund Thompson Street Capital Partners, in its strategic acquisition of ONFAB from Foresight Capital Partners.
• Peprotech Inc., a leading manufacturer of cytokines and antibodies for scientific application in relation to various corporate matters, and advising in relation to its sale for US$1.85 billion.
• San Reno Therapeutics on its acquisition by Novartis.
• Sedgwick Claims Management (then a KKR portfolio company) in relation to its acquisition of Cunningham Lindsey in the insurance sector.
• Cerberus Capital Management on the sale of Covis Pharma to funds managed by Apollo Global Management.
• A global private equity fund on its €1 billion bid to acquire a global healthcare group from another global private equity fund.
• Carlin Consumer Health in relation to the acquisition of Infirst Healthcare Inc. (marketer of Mylanta® and Mylicon®).
• The founder of Base Genomics on its sale to Exact Sciences for US$410 million.
• Judges Scientific plc in relation to over 15 acquisitions in the Life Sciences and Engineering sectors.
• Advent International in relation to the disposal of Oxea, one of the largest global manufacturers of Oxo chemicals, to Oman Oil Company, for US$2.4 billion.
• Mitsubishi Heavy Industries on its multi-billion dollar global joint venture in metals machinery technology (with Siemens AG).
• Lynwood Investments in relation to its sale of some of its interest in Waterstones Booksellers to Elliott Private Equity.

Growth Capital and Venture Capital

• OrbiMed and RA Capital Management in relation to the US$410 million equity investment in Verdiva Bio.
• Novo Holdings on its £50 million investment in Oxford Nanopore Technologies.
• OrbiMed and RA Capital in relation to the US$410 million equity investment in Verdiva Bio.
• The Craftory, the US$585 million challenger-brand investment fund, in relation to its structuring and equity funding by three of the world’s largest family offices.
• Perspectum Group Limited on its US$55 million Series C lead by Oppenheimer Holdings.
• BeiGene in relation to licensing and investment in a Swiss biotech.
• One of the world’s largest family offices in relation to investments in the Life Sciences and Technology sectors.
• Funds advised by RedMile LLC in relation to the US$189 million Series C and D of Agomab Therapeutics NV.
• Funds advised by Orbimed Advisors LLC in relation to an investment in a UK biotech group.

Complex Licensing and Collaborations

• Juniper Biologics on its licensing and collaboration agreements with Helsinn S.A.(Aloxi, Akynzeo, Anamorelin, and Truseltiq) and Kolon Life Sciences (TG-C).
• BigHat Biosciences Inc. in a licensing and collaboration agreement with Synaffix B.V., a Lonza company.
• London Zoo in relation to various commercial aspects of its operations, including negotiations with the UK Government.
• The government of a country in south-eastern Europe in relation to its COVID-19 vaccine procurement program.
• Roha Africa in relation to hospital management arrangements relating to Roha Medical Campus in Addis Ababa, Ethiopia.
• Huma on a collaboration agreement with a global pharmaceutical company.
• BeiGene in relation to various commercial matters.

Some of the above matters were handled prior to joining Sidley.

• Finance and Technical Committee, Biotech Industry Association